A Double Blind, Placebo-controlled First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK3036656 in Healthy Adult Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs GSK 3036656 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 03 Aug 2017 Planned End Date changed from 25 Jul 2017 to 4 Aug 2017.
- 03 Aug 2017 Planned primary completion date changed from 25 Jul 2017 to 4 Aug 2017.
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.